Catalent and Bhami Research Laboratory Enter Into Licensing Agreement for Technology to Deliver High-Concentration Biologics Subcutaneously
March 17, 2023
March 17, 2023
SOMERSET, New Jersey, March 17 (TNSres) -- Catalent Inc., a pharma, biotech and consumer health company, issued the following news on March 16, 2023:
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Bhami Research Laboratory (BRL), today announced a licensing agreement that will provide Catalent with access to BRL's formulation technology to help enable the subcutaneous delivery of high-concentration biologic therapies . . .
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Bhami Research Laboratory (BRL), today announced a licensing agreement that will provide Catalent with access to BRL's formulation technology to help enable the subcutaneous delivery of high-concentration biologic therapies . . .